首页 > 医客百宝箱 > 资料合集 > 详情

2024ASCO Oral原版幻灯合集

2024年美国临床肿瘤学会（ASCO）年会于美国中部夏令时间5月31日至6月4日在美国芝加哥举行。作为全球最顶级临床肿瘤学术会议之一，汇集了来自世界各地的34000余名肿瘤学专业人士。会议形式多样，教育课程以世界知名的教师为特色，讨论最先进的治疗方式、新疗法和该领域正在进行的争议；科学会议以口头及壁报等形式展示最新的突破性研究成果。

打包价：300 微豆

原价：1845 微豆 / 共123份资料

资料合集

MOUNTAINEER FINAL RESULTS OF APHASE 2 STUDY OF TUCATINIB ANDTRASTUZUMAB FOR HER2-POSITIVEMETASTATIC CRC

15 微豆

Neoadiuvant Pembrolizumab stratified to tumourmutation burden for High-Risk Stage 2 or Stage 3deficient-MMRMSl-High Colorectal CancerThe multicentre Phase 2 NEOPRISM-CRC trial

15 微豆

Neoadjuvant treatment of lBl310 (anti-CTLA-4 antibody) plus sintilimab(anti-PD.1 antibody) in patients with microsatellite instabilityhighmismatchrepair-deficient colon cancer Results from a randomiz

15 微豆

Nivolumab plus ipilimumab vs chemotherapy as first-linetreatment for microsatellite instability-highmismatchrepairdeficient metastatic colorectal cancer expandedefficacy analysis from CheckMate 8HW

15 微豆

Orchestrating a Collision with LiverTransplant for Colorectal Cancer

15 微豆

Overall survival (oS) of phase 3 CodeBreak 300 study ofsotorasib plus panitumumab (soto pani) versus investigator'schoice of therapy for KRAS G12c-mutated metastatic colorectacancer (mCRc)

15 微豆

Phase l trial of hypoxia-responsive CEA CAR-T celltherapy in patients with heavily pretreated solid tumorvia intraperitoneal or intravenous transfusion

15 微豆

Primary Endpoint Analysis of the ORCHESTRA TRIAL

15 微豆

Three-year disease-free survival after transanal vsaparoscopic total mesorectal excision for rectalcancer (TaLaR)A randomized clinical trial

15 微豆

Time dependency for HPV ctDNAdetection as a prognostic biomarkerfor anal cancer

15 微豆